secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2023-06-26T23:59:59+00:00
Accession:  0001104659-23-074439
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion reports 30% MACE-4 risk reduction with bempedoic acid in primary prevention CLEAR Outcomes subanalysis
--------------------------------------------------------------------------------

- Primary prevention population (4,206 statin-intolerant patients) showed 30% risk reduction in MACE-4 (HR 0.70) vs placebo.
- 36% MACE-3 risk reduction (HR 0.64) and 39% reduction in CV mortality (HR 0.61).
- All-cause mortality reduced by 27% (HR 0.73). LDL-C lowered 21.3% after 6 months; hsCRP lowered 21.5% after 12 months.
- Data presented at ADA 2023 and simultaneously published in JAMA on June 24, 2023.
- Nearly two-thirds (66.1%) of primary prevention patients had diabetes; safety consistent with prior trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000110465923074439/0001104659-23-074439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000110465923074439/tm2319637d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-074439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer